217 related articles for article (PubMed ID: 22180752)
1. Structural Basis for the Antiviral Activity of BST-2/Tetherin and Its Viral Antagonism.
Arias JF; Iwabu Y; Tokunaga K
Front Microbiol; 2011; 2():250. PubMed ID: 22180752
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates.
Chen CY; Shingai M; Welbourn S; Martin MA; Borrego P; Taveira N; Strebel K
J Virol; 2016 Dec; 90(24):11062-11074. PubMed ID: 27681141
[TBL] [Abstract][Full Text] [Related]
4. Identification of Residues in the BST-2 TM Domain Important for Antagonism by HIV-1 Vpu Using a Gain-of-Function Approach.
Yoshida T; Kao S; Strebel K
Front Microbiol; 2011; 2():35. PubMed ID: 21687426
[TBL] [Abstract][Full Text] [Related]
5. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
Van Damme N; Goff D; Katsura C; Jorgenson RL; Mitchell R; Johnson MC; Stephens EB; Guatelli J
Cell Host Microbe; 2008 Apr; 3(4):245-52. PubMed ID: 18342597
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel key amino acids at the interface of the transmembrane domains of human BST-2 and HIV-1 Vpu.
Pang X; Hu S; Li J; Xu F; Mei S; Zhou J; Cen S; Jin Q; Guo F
Retrovirology; 2013 Aug; 10():84. PubMed ID: 23919512
[TBL] [Abstract][Full Text] [Related]
7. Sites of action of HIV-1 Vpu in BST-2/tetherin downregulation.
Arias JF; Iwabu Y; Tokunaga K
Curr HIV Res; 2012 Jun; 10(4):283-91. PubMed ID: 22524176
[TBL] [Abstract][Full Text] [Related]
8. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.
Fitzpatrick K; Skasko M; Deerinck TJ; Crum J; Ellisman MH; Guatelli J
PLoS Pathog; 2010 Mar; 6(3):e1000701. PubMed ID: 20221443
[TBL] [Abstract][Full Text] [Related]
9. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
10. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.
Lau D; Kwan W; Guatelli J
J Virol; 2011 Oct; 85(19):9834-46. PubMed ID: 21813615
[TBL] [Abstract][Full Text] [Related]
11. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.
Lopez LA; Yang SJ; Hauser H; Exline CM; Haworth KG; Oldenburg J; Cannon PM
J Virol; 2010 Jul; 84(14):7243-55. PubMed ID: 20444895
[TBL] [Abstract][Full Text] [Related]
12. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.
Tokarev A; Skasko M; Fitzpatrick K; Guatelli J
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1197-210. PubMed ID: 19929170
[TBL] [Abstract][Full Text] [Related]
14. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
[TBL] [Abstract][Full Text] [Related]
15. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
[TBL] [Abstract][Full Text] [Related]
16. Early Vertebrate Evolution of the Host Restriction Factor Tetherin.
Heusinger E; Kluge SF; Kirchhoff F; Sauter D
J Virol; 2015 Dec; 89(23):12154-65. PubMed ID: 26401043
[TBL] [Abstract][Full Text] [Related]
17. C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif.
Andrew AJ; Kao S; Strebel K
J Biol Chem; 2011 Nov; 286(46):39967-81. PubMed ID: 21937450
[TBL] [Abstract][Full Text] [Related]
18. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
[TBL] [Abstract][Full Text] [Related]
19. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility.
Kobayashi T; Ode H; Yoshida T; Sato K; Gee P; Yamamoto SP; Ebina H; Strebel K; Sato H; Koyanagi Y
J Virol; 2011 Jan; 85(2):932-45. PubMed ID: 21068238
[TBL] [Abstract][Full Text] [Related]
20. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants.
McNatt MW; Zang T; Hatziioannou T; Bartlett M; Fofana IB; Johnson WE; Neil SJ; Bieniasz PD
PLoS Pathog; 2009 Feb; 5(2):e1000300. PubMed ID: 19214216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
